Document And Entity Information
| Document And Entity Information - shares | 9 Months Ended | |
| Sep. 30, 2018 | Nov. 02, 2018 | |
| Document Information [Line Items] | ||
| Entity Registrant Name | BioCardia, Inc. | |
| Entity Central Index Key | 925,741 | |
| Trading Symbol | bcda | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Filer Category | Accelerated Filer | |
| Entity Current Reporting Status | Yes | |
| Entity Emerging Growth Company | false | |
| Entity Small Business | false | |
| Entity Common Stock, Shares Outstanding (in shares) | 38,277,908 | |
| Document Type | 10-Q | |
| Document Period End Date | Sep. 30, 2018 | |
| Document Fiscal Year Focus | 2,018 | |
| Document Fiscal Period Focus | Q3 | |
| Amendment Flag | false |
Condensed Consolidated Balance
| Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Sep. 30, 2018 | Dec. 31, 2017 |
| Current assets: | ||
| Cash and cash equivalents | $ 4,820 | $ 12,689 |
| Accounts receivable, net of allowance for doubtful accounts of $6 and $6 at September 30, 2018 and December 31, 2017, respectively | 170 | 95 |
| Inventory | 134 | 191 |
| Prepaid expenses | 224 | 340 |
| Total current assets | 5,348 | 13,315 |
| Property and equipment, net | 154 | 169 |
| Other assets | 54 | 54 |
| Total assets | 5,556 | 13,538 |
| Current liabilities: | ||
| Accounts payable | 1,102 | 902 |
| Accrued expenses and other current liabilities | 1,430 | 1,263 |
| Deferred revenue | 167 | |
| Total current liabilities | 2,532 | 2,332 |
| Deferred rent | 80 | 81 |
| Total liabilities | 2,612 | 2,413 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 25,000,000 shares authorized; no shares issued and outstanding as of September 30, 2018 and December 31, 2017 | ||
| Common stock, $0.001 par value, 100,000,000 shares authorized as of September 30, 2018 and December 31, 2017 respectively; 38,277,908 and 38,218,660 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively | 38 | 38 |
| Additional paid-in capital | 85,625 | 83,537 |
| Accumulated deficit | (82,719) | (72,450) |
| Total stockholders’ equity | 2,944 | 11,125 |
| Total liabilities and stockholders’ equity | $ 5,556 | $ 13,538 |
Condensed Consolidated Balanc_2
| Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Sep. 30, 2018 | Dec. 31, 2017 |
| Allowance for doubtful accounts | $ 6 | $ 6 |
| Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
| Preferred stock, shares authorized (in shares) | 25,000,000 | 25,000,000 |
| Preferred stock, shares issued (in shares) | 0 | 0 |
| Preferred stock, shares outstanding (in shares) | 0 | 0 |
| Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
| Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
| Common stock, shares issued (in shares) | 38,277,908 | 38,218,660 |
| Common stock, shares outstanding (in shares) | 38,277,908 | 38,218,660 |
Condensed Consolidated Statemen
| Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
| Revenue: | ||||
| Total revenue | $ 84 | $ 130 | $ 522 | $ 379 |
| Costs and expenses: | ||||
| Cost of goods sold | 109 | 147 | 401 | 525 |
| Research and development | 2,262 | 1,700 | 6,248 | 4,028 |
| Selling, general and administrative | 1,283 | 1,322 | 4,315 | 4,708 |
| Total costs and expenses | 3,654 | 3,169 | 10,964 | 9,261 |
| Operating loss | (3,570) | (3,039) | (10,442) | (8,882) |
| Other income (expense): | ||||
| Interest income | 29 | 35 | 100 | 58 |
| Other expense, net | (3) | 3 | (3) | 2 |
| Total other income, net | 26 | 38 | 97 | 60 |
| Net loss | $ (3,544) | $ (3,001) | $ (10,345) | $ (8,822) |
| Net loss per share, basic and diluted (in dollars per share) | $ (0.09) | $ (0.08) | $ (0.27) | $ (0.23) |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 38,277,908 | 38,146,751 | 38,254,583 | 38,141,654 |
| Product [Member] | ||||
| Revenue: | ||||
| Total revenue | $ 52 | $ 88 | $ 223 | $ 298 |
| Collaboration Agreement [Member] | ||||
| Revenue: | ||||
| Total revenue | $ 32 | $ 42 | $ 299 | $ 81 |
Condensed Consolidated Statem_2
| Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
| Sep. 30, 2018 | Sep. 30, 2017 | |
| Operating activities: | ||
| Net loss | $ (10,345) | $ (8,822) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 66 | 57 |
| Share-based compensation | 2,083 | 1,999 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (75) | (16) |
| Inventory | 57 | (105) |
| Prepaid expenses | 116 | 168 |
| Accounts payable | 200 | (80) |
| Accrued liabilities | 141 | 545 |
| Deferred revenue | (65) | 89 |
| Deferred rent | (1) | 19 |
| Net cash used in operating activities | (7,823) | (6,146) |
| Investing activities: | ||
| Purchase of property and equipment | (51) | (107) |
| Purchase of short-term investments | (1,799) | |
| Net used in in investing activities | (51) | (1,906) |
| Financing activities: | ||
| Proceeds from the exercise of common stock options | 5 | 26 |
| Net cash provided by financing activities | 5 | 26 |
| Net decrease in cash and cash equivalents | (7,869) | (8,026) |
| Cash and cash equivalents at beginning of period | 12,689 | 21,352 |
| Cash and cash equivalents at end of period | $ 4,820 | $ 13,326 |
Note 1 - Summary of Business an
| Note 1 - Summary of Business and Basis of Presentation | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Business Description and Basis of Presentation [Text Block] | ( 1 Summary of Business and Basis of Presentation Description of Business BioCardia, Inc., (“we” or “the Company”), is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Our lead therapeutic candidate is the CardiAMP Cell Therapy System, an investigational autologous bone marrow derived cell therapy being advanced for two second not We have three one 1 2 3 |
Note 2 - Significant Accounting
| Note 2 - Significant Accounting Policies | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Significant Accounting Policies [Text Block] | ( 2 Significant Accounting Policies (a) Basis of Preparation The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of and for the three nine September 30, 2018 2017 three nine September 30, 2018 not December 31, 2018 These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10 December 31, 2017, March 16, 2018. (b) Liquidity We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of $82.7 September 30, 2018. $4.8 September 30, 2018 Q1 2019. one not Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP Cell Therapy System, and our second Q1 2019, not may may no (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation. (d) Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process. (e) Changes to Significant Accounting Policies Our significant accounting policies are described in Note 2 10 December 31, 2017. No. 2014 09, 606 January 1, 2018, no Revenue Recognition Net product revenue Collaboration agreement revenue Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets. (f) Recently Adopted Accounting Pronouncement In May 2014, 606, 606 On January 1, 2018, 606 January 1, 2018 606, not 605. $76,000 January 1, 2018 606, In January 2016, No. 2016 01 2016 01 2016 01 2016 01 January 1, 2018 not In May 2017, No. 2017 09 718 2017 09 2017 09 718. 2017 09 January 1, 2018, not (g) Recently Issued Accounting Pronouncements In February 2016, No. 2016 02 842 2016 02 840 2016 02 December 15, 2018; 2016 02 may January 1, 2019. January 1, 2019 not not January 1, 2019. not not not 1 2 not In June 2018, 2018 07 718 2018 07 2018 07 718 2018 07 December 15, 2018 January 1, 2019 Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not not |
Note 3 - Fair Value Measurement
| Note 3 - Fair Value Measurement | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Fair Value Disclosures [Text Block] | ( 3 Fair Value Measurement The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three Level 1 Level 2 not Level 3 no The following table sets forth the fair value of our financial assets measured on a recurring basis as of September 30, 2018 December 31, 2017 As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 4,854 $ — $ — $ 4,854 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 12,063 $ — $ — $ 12,063 |
Note 4 - Inventories
| Note 4 - Inventories | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Inventory Disclosure [Text Block] | ( 4 Inventories Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of the following (in thousands): September 30, December 31, 2017 Raw materials $ 62 $ 70 Work in process 3 92 Finished goods 69 29 Total $ 134 $ 191 Write downs for excess or expired inventory are based on management’s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts may $13,000 $15,000 three September 30, 2018 2017 $15,000 $25,000 nine September 30, 2018 2017, |
Note 5 - Property and Equipment
| Note 5 - Property and Equipment, Net | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Property, Plant and Equipment Disclosure [Text Block] | ( 5 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): September 30, December 31, Computer equipment and software $ 116 $ 106 Laboratory and manufacturing equipment 474 447 Furniture and fixtures 55 48 Leasehold improvements 331 326 Construction in progress 1 — Property and equipment, gross 977 927 Less accumulated depreciation (823 ) (758 ) Property and equipment, net $ 154 $ 169 |
Note 6 - Accrued Expenses and O
| Note 6 - Accrued Expenses and Other Current Liabilities | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Accrued Liabilities and Other Current Liabilities Disclosure [Text Block] | ( 6 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, December 31, Accrued expenses $ 226 $ 129 Accrued employee costs 455 410 Grant liability 666 663 Customer deposits 83 61 Total $ 1,430 $ 1,263 |
Note 7 - Share-based Compensati
| Note 7 - Share-based Compensation | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | ( 7 Share-Based Compensation The share-based compensation expense is recorded in cost of goods sold, research and development, and selling, general and administrative expenses based on the employee's respective function. No three nine September 30, 2018 2017 Three months ended September 30, Nine months ended September 30, 2018 2017 2018 2017 Cost of goods sold $ 39 $ 33 $ 105 $ 107 Research and development 250 172 711 498 Selling, general and administrative 441 496 1,267 1,394 Share-based compensation expense $ 730 $ 701 $ 2,083 $ 1,999 The following table summarizes the activity of stock options and related information: Number of options outstanding Weighted average exercise price Balance, December 31, 2017 4,213,100 $ 2.96 Stock options granted 1,698,452 2.41 Stock options exercised (2,488 ) 1.80 Stock options cancelled (359,958 ) 2.93 Balance, September 30, 2018 5,549,106 $ 2.80 The weighted average grant-date fair value of options granted during the nine September 30, 2018 $1.72 Employee Share-Based Compensation (Stock Options) During the nine September 30, 2018, 1,698,452 Risk-free interest rate 2.66% - 2.87% Volatility 81% - 82% Dividend yield None Expected term (in years) 6.25 Unrecognized share-based compensation for employee options as of September 30, 2018 $5.6 2.7 Restricted Stock Units (RSUs) The following summarizes the activity of non-vested RSUs: Number of shares Weighted average grant date fair value per share Balance, December 31, 2017 97,996 $ 8.71 RSUs granted 226,471 1.36 RSUs vested (57,108 ) 7.03 Balance, September 30, 2018 267,359 $ 2.84 Unrecognized share-based compensation for employee RSUs granted as of September 30, 2018 $292,000 1.3 Nonemployee Share-Based Compensation During the nine September 30, 2018, not $74,000 $188,000 three September 30, 2018 2017, $150,000 $698,000 nine September 30, 2018 2017, We account for share-based compensation arrangements with nonemployees, using the Black-Scholes option pricing model, based on the fair value as these instruments vest. Accordingly, at each reporting date, we revalue the unearned portion of the share-based compensation and the resulting change in fair value is recognized in the consolidated statements of operations over the period the related services are rendered. The following assumptions were used to value the awards for the nine September 30, 2018: Risk-free interest rate 2.80% - 2.84% Volatility 78% - 85% Dividend yield None Expected term (in years) 7.9 - 8.8 |
Note 8 - Net Loss Per Share
| Note 8 - Net Loss Per Share | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Earnings Per Share [Text Block] | ( 8 Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: September 30, 2018 2017 Stock options to purchase common stock 5,549,106 4,142,692 Unvested restricted stock units 267,359 97,996 Total 5,816,465 4,240,688 |
Note 9 - Income Taxes
| Note 9 - Income Taxes | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Income Tax Disclosure [Text Block] | ( 9 Income Taxes During the nine September 30, 2018 2017, no As of September 30, 2018, not not On December 22, 2017, 1 35% 21% The 2017 2018 118, No nine September 30, 2018. |
Note 10 - Related Party Transac
| Note 10 - Related Party Transactions | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes to Financial Statements | |
| Related Party Transactions Disclosure [Text Block] | ( 10 Related Party Transactions In August 2016, 418,977 four $1.80 $121,000 $432,000 nine September 30, 2018 2017, $5.3 four one 5% 5% |
Significant Accounting Policies
| Significant Accounting Policies (Policies) | 9 Months Ended |
| Sep. 30, 2018 | |
| Accounting Policies [Abstract] | |
| Basis of Accounting, Policy [Policy Text Block] | (a) Basis of Preparation The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of and for the three nine September 30, 2018 2017 three nine September 30, 2018 not December 31, 2018 These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10 December 31, 2017, March 16, 2018. |
| Going Concern and Liquidity [Policy Text Block] | (b) Liquidity We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of $82.7 September 30, 2018. $4.8 September 30, 2018 Q1 2019. one not Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP Cell Therapy System, and our second Q1 2019, not may may no |
| Use of Estimates, Policy [Policy Text Block] | (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation. |
| Consolidation, Policy [Policy Text Block] | (d) Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process. |
| Revenue from Contract with Customer [Policy Text Block] | (e) Changes to Significant Accounting Policies Our significant accounting policies are described in Note 2 10 December 31, 2017. No. 2014 09, 606 January 1, 2018, no Revenue Recognition Net product revenue Collaboration agreement revenue Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets. |
| New Accounting Pronouncements, Policy [Policy Text Block] | (f) Recently Adopted Accounting Pronouncement In May 2014, 606, 606 On January 1, 2018, 606 January 1, 2018 606, not 605. $76,000 January 1, 2018 606, In January 2016, No. 2016 01 2016 01 2016 01 2016 01 January 1, 2018 not In May 2017, No. 2017 09 718 2017 09 2017 09 718. 2017 09 January 1, 2018, not (g) Recently Issued Accounting Pronouncements In February 2016, No. 2016 02 842 2016 02 840 2016 02 December 15, 2018; 2016 02 may January 1, 2019. January 1, 2019 not not January 1, 2019. not not not 1 2 not In June 2018, 2018 07 718 2018 07 2018 07 718 2018 07 December 15, 2018 January 1, 2019 Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not not |
Note 3 - Fair Value Measureme_2
| Note 3 - Fair Value Measurement (Tables) | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes Tables | |
| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 4,854 $ — $ — $ 4,854 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 12,063 $ — $ — $ 12,063 |
Note 4 - Inventories (Tables)
| Note 4 - Inventories (Tables) | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes Tables | |
| Schedule of Inventory, Current [Table Text Block] | September 30, December 31, 2017 Raw materials $ 62 $ 70 Work in process 3 92 Finished goods 69 29 Total $ 134 $ 191 |
Note 5 - Property and Equipme_2
| Note 5 - Property and Equipment, Net (Tables) | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes Tables | |
| Property, Plant and Equipment [Table Text Block] | September 30, December 31, Computer equipment and software $ 116 $ 106 Laboratory and manufacturing equipment 474 447 Furniture and fixtures 55 48 Leasehold improvements 331 326 Construction in progress 1 — Property and equipment, gross 977 927 Less accumulated depreciation (823 ) (758 ) Property and equipment, net $ 154 $ 169 |
Note 6 - Accrued Expenses and_2
| Note 6 - Accrued Expenses and Other Current Liabilities (Tables) | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes Tables | |
| Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block] | <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,<br /> 2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,<br /> 2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">226</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued employee costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">455</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">410</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Grant liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">666</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,430</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>" id="sjs-B4"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,<br /> 2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,<br /> 2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">226</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued employee costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">455</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">410</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Grant liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">666</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,430</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> |
Note 7 - Share-based Compensa_2
| Note 7 - Share-based Compensation (Tables) | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes Tables | |
| Schedule of Share-based Compensation, Expense [Table Text Block] | Three months ended September 30, Nine months ended September 30, 2018 2017 2018 2017 Cost of goods sold $ 39 $ 33 $ 105 $ 107 Research and development 250 172 711 498 Selling, general and administrative 441 496 1,267 1,394 Share-based compensation expense $ 730 $ 701 $ 2,083 $ 1,999 |
| Share-based Compensation, Stock Options, Activity [Table Text Block] | Number of options outstanding Weighted average exercise price Balance, December 31, 2017 4,213,100 $ 2.96 Stock options granted 1,698,452 2.41 Stock options exercised (2,488 ) 1.80 Stock options cancelled (359,958 ) 2.93 Balance, September 30, 2018 5,549,106 $ 2.80 |
| Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] | Number of shares Weighted average grant date fair value per share Balance, December 31, 2017 97,996 $ 8.71 RSUs granted 226,471 1.36 RSUs vested (57,108 ) 7.03 Balance, September 30, 2018 267,359 $ 2.84 |
| Non-employee Stock Options [Member] | |
| Notes Tables | |
| Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Risk-free interest rate 2.80% - 2.84% Volatility 78% - 85% Dividend yield None Expected term (in years) 7.9 - 8.8 |
| Employee Stock Option [Member] | |
| Notes Tables | |
| Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Risk-free interest rate 2.66% - 2.87% Volatility 81% - 82% Dividend yield None Expected term (in years) 6.25 |
Note 8 - Net Loss Per Share (Ta
| Note 8 - Net Loss Per Share (Tables) | 9 Months Ended |
| Sep. 30, 2018 | |
| Notes Tables | |
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | September 30, 2018 2017 Stock options to purchase common stock 5,549,106 4,142,692 Unvested restricted stock units 267,359 97,996 Total 5,816,465 4,240,688 |
Note 2 - Significant Accounti_2
| Note 2 - Significant Accounting Policies (Details Textual) - USD ($) | Sep. 30, 2018 | Jan. 01, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Dec. 31, 2016 |
| Retained Earnings (Accumulated Deficit), Ending Balance | $ (82,719,000) | $ (72,450,000) | |||
| Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 4,820,000 | $ 12,689,000 | $ 13,326,000 | $ 21,352,000 | |
| Accounting Standards Update 2014-09 [Member] | |||||
| Retained Earnings (Accumulated Deficit), Ending Balance | $ (76,000) |
Note 3 - Fair Value Measureme_3
| Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands | Sep. 30, 2018 | Dec. 31, 2017 |
| Assets: | ||
| Cash equivalents | $ 4,854 | $ 12,063 |
| Fair Value, Inputs, Level 1 [Member] | ||
| Assets: | ||
| Cash equivalents | 4,854 | 12,063 |
| Fair Value, Inputs, Level 2 [Member] | ||
| Assets: | ||
| Cash equivalents | ||
| Fair Value, Inputs, Level 3 [Member] | ||
| Assets: | ||
| Cash equivalents |
Note 4 - Inventories (Details T
| Note 4 - Inventories (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
| Inventory Write-down | $ 13,000 | $ 15,000 | $ 15,000 | $ 25,000 |
Note 4 - Inventories - Summary
| Note 4 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands | Sep. 30, 2018 | Dec. 31, 2017 |
| Raw materials | $ 62 | $ 70 |
| Work in process | 3 | 92 |
| Finished goods | 69 | 29 |
| Total | $ 134 | $ 191 |
Note 5 - Property and Equipme_3
| Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands | Sep. 30, 2018 | Dec. 31, 2017 |
| Property and equipment, gross | $ 977 | $ 927 |
| Less accumulated depreciation | (823) | (758) |
| Property and equipment, net | 154 | 169 |
| Computer Equipment and Software [Member] | ||
| Property and equipment, gross | 116 | 106 |
| Laboratory and Manufacturing Equipment [Member] | ||
| Property and equipment, gross | 474 | 447 |
| Furniture and Fixtures [Member] | ||
| Property and equipment, gross | 55 | 48 |
| Leasehold Improvements [Member] | ||
| Property and equipment, gross | 331 | 326 |
| Construction in Progress [Member] | ||
| Property and equipment, gross | $ 1 |
Note 6 - Accrued Expenses and_3
| Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2018 | Dec. 31, 2017 |
| Accrued expenses | $ 226 | $ 129 |
| Accrued employee costs | 455 | 410 |
| Grant liability | 666 | 663 |
| Customer deposits | 83 | 61 |
| Total | $ 1,430 | $ 1,263 |
Note 7 - Share-based Compensa_3
| Note 7 - Share-based Compensation (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
| Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount | $ 0 | $ 0 | $ 0 | $ 0 |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 1.72 | |||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,698,452 | |||
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | 5,600,000 | $ 5,600,000 | ||
| Allocated Share-based Compensation Expense, Total | 730,000 | 701,000 | $ 2,083,000 | 1,999,000 |
| Consultants [Member] | ||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 0 | |||
| Non-employees [Member] | ||||
| Allocated Share-based Compensation Expense, Total | 74,000 | $ 188,000 | $ 150,000 | $ 698,000 |
| Employee Stock Option [Member] | ||||
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 255 days | |||
| Restricted Stock Units (RSUs) [Member] | ||||
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 109 days | |||
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options | $ 292,000 | $ 292,000 | ||
Note 7 - Share-based Compensa_4
| Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
| Share-based compensation expense | $ 730 | $ 701 | $ 2,083 | $ 1,999 |
| Cost of Goods Sold [Member] | ||||
| Share-based compensation expense | 39 | 33 | 105 | 107 |
| Research and Development Expense [Member] | ||||
| Share-based compensation expense | 250 | 172 | 711 | 498 |
| Selling, General and Administrative Expenses [Member] | ||||
| Share-based compensation expense | $ 441 | $ 496 | $ 1,267 | $ 1,394 |
Note 7 - Share-based Compensa_5
| Note 7 - Share-based Compensation - Stock Option Activity (Details) | 9 Months Ended |
| Sep. 30, 2018$ / sharesshares | |
| Stock options outstanding, beginning of period (in shares) | shares | 4,213,100 |
| Balance, weighted average exercise price, beginning of period (in dollars per share) | $ / shares | $ 2.96 |
| Stock options granted (in shares) | shares | 1,698,452 |
| Stock options granted, weighted average exercise price (in dollars per share) | $ / shares | $ 2.41 |
| Stock options exercised (in shares) | shares | (2,488) |
| Stock options exercised, weighted average exercise price (in dollars per share) | $ / shares | $ 1.80 |
| Stock options cancelled (in shares) | shares | (359,958) |
| Stock options cancelled, weighted average exercise price (in dollars per share) | $ / shares | $ 2.93 |
| Stock options outstanding, end of period (in shares) | shares | 5,549,106 |
| Balance, weighted average exercise price, end of period (in dollars per share) | $ / shares | $ 2.80 |
Note 7 - Share-based Compensa_6
| Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) - Employee Stock Option [Member] | 9 Months Ended |
| Sep. 30, 2018 | |
| Risk-free interest rate | |
| Volatility | |
| Dividend yield | 0.00% |
| Expected term (Year) | 6 years 91 days |
| Minimum [Member] | |
| Risk-free interest rate | 2.66% |
| Volatility | 81.00% |
| Dividend yield | |
| Expected term (Year) | |
| Maximum [Member] | |
| Risk-free interest rate | 2.87% |
| Volatility | 82.00% |
| Dividend yield | |
| Expected term (Year) |
Note 7 - Share-based Compensa_7
| Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) - Restricted Stock Units (RSUs) [Member] | 9 Months Ended |
| Sep. 30, 2018$ / sharesshares | |
| Balance, Shares (in shares) | shares | 97,996 |
| Balance, Weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 8.71 |
| RSUs granted, shares (in shares) | shares | 226,471 |
| RSUs granted, Weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 1.36 |
| RSUs vested, Shares (in shares) | shares | (57,108) |
| RSUs vested, Weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 7.03 |
| Balance, Shares (in shares) | shares | 267,359 |
| Balance, Weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 2.84 |
Note 7 - Share-based Compensa_8
| Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) - Non-employee Stock Options [Member] | 9 Months Ended |
| Sep. 30, 2018 | |
| Dividend yield | 0.00% |
| Minimum [Member] | |
| Risk-free interest rate | 2.80% |
| Volatility | 78.00% |
| Expected term (Year) | 7 years 328 days |
| Maximum [Member] | |
| Risk-free interest rate | 2.84% |
| Volatility | 85.00% |
| Expected term (Year) | 8 years 292 days |
Note 8 - Net Loss Per Share - A
| Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares | 9 Months Ended | |
| Sep. 30, 2018 | Sep. 30, 2017 | |
| Antidilutive securities (in shares) | 5,816,465 | 4,240,688 |
| Employee Stock Option [Member] | ||
| Antidilutive securities (in shares) | 5,549,106 | 4,142,692 |
| Restricted Stock Units (RSUs) [Member] | ||
| Antidilutive securities (in shares) | 267,359 | 97,996 |
Note 9 - Income Taxes (Details
| Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | ||
| Sep. 30, 2018 | Sep. 30, 2017 | Dec. 31, 2018 | Dec. 31, 2017 | |
| Income Tax Expense (Benefit), Total | $ 0 | $ 0 | ||
| Deferred Tax Liabilities, Net, Total | $ 0 | |||
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 35.00% | |||
| Scenario, Forecast [Member] | ||||
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | |||
Note 10 - Related Party Trans_2
| Note 10 - Related Party Transactions (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
| Aug. 31, 2016 | Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | Dec. 31, 2017 | |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,698,452 | |||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ 2.80 | $ 2.80 | $ 2.96 | |||
| Allocated Share-based Compensation Expense, Total | $ 730,000 | $ 701,000 | $ 2,083,000 | $ 1,999,000 | ||
| OPKO [Member] | ||||||
| Related Party, Ownership Percentage | 5.00% | |||||
| OPKO [Member] | Consulting Services [Member] | ||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 418,977 | |||||
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ 1.80 | |||||
| Allocated Share-based Compensation Expense, Total | 121,000 | $ 432,000 | ||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Grant Date Fair Value | $ 5,300,000 | $ 5,300,000 | ||||
| Consulting Agreement, Term | 4 years | |||||
| Consulting Agreement, Term, Length of Automatic Renewal Periods | 1 year | |||||
| Chairman and Chief Executive Officer of OPKO [Member] | ||||||
| Related Party, Ownership Percentage | 5.00% | |||||